BiotechTubeBiotechTube
Home/Tempest Therapeutics/Bessie So
BS

Bessie So

Chief Financial Officer

Tempest Therapeutics

Therapeutic Areas

Oncology

Tempest Therapeutics Pipeline

DrugIndicationPhase
TPST-1120Advanced solid tumors (e.g., renal cell carcinoma, cholangiocarcinoma)Phase 1/2
TPST-1495Advanced solid tumors (e.g., endometrial cancer)Phase 1/2

Leadership Team at Tempest Therapeutics

SR
Stephen R. Brady
Chief Executive Officer
TD
Tom Dubensky
President
SW
Sam Whiting
Chief Medical Officer and Head of Development
DH
David H. Mack
Chief Scientific Officer
NM
Nicholas Maestas
Vice President, Investor Relations & Corporate Communications
JK
John K. H. H.
Chairman of the Board
WL
Wendy L. Dixon
Director
KV
Katherine V. T. Schreck
Director
View full Tempest Therapeutics profile